Literature DB >> 17018784

Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.

Andrés J M Ferreri1, Maurilio Ponzoni, Massimo Guidoboni, Antonio Giordano Resti, Letterio S Politi, Sergio Cortelazzo, Judit Demeter, Francesco Zallio, Angelo Palmas, Giuliana Muti, Giuseppina P Dognini, Elisa Pasini, Antonia Anna Lettini, Federico Sacchetti, Carlo De Conciliis, Claudio Doglioni, Riccardo Dolcetti.   

Abstract

BACKGROUND: An association between ocular adnexal MALT lymphoma (OAL) and Chlamydia psittaci (Cp) infection has been proposed, and recent reports suggest that doxycycline treatment causes tumor regression in patients with Cp-related OAL. The effectiveness of doxycycline treatment in Cp-negative OAL has not been tested.
METHODS: In a prospective trial, 27 OAL patients (15 newly diagnosed and 12 having experienced relapse) were given a 3-week course of doxycycline therapy. Objective lymphoma response was assessed by computerized tomography scans or magnetic resonance imaging at 1, 3, and 6 months after the conclusion of therapy and every 6 months during follow-up. Cp infection in patients was determined by touchdown enzyme time-release polymerase chain reaction (TETR-PCR). Statistical tests were two-sided.
RESULTS: Eleven patients were Cp DNA-positive and 16 were Cp DNA negative. Doxycycline was well tolerated. At a median follow-up of 14 months, lymphoma regression was complete in six patients, and a partial response (> or = 50% reduction of all measurable lesions) was observed in seven patients (overall response rate [complete and partial responses] = 48%). Lymphoma regression was observed in both Cp DNA-positive patients (seven of 11 experienced regression) and Cp DNA-negative patients (six of 16 experienced regression) (64% versus 38%; P = .25, Fisher's exact test). The three patients with regional lymphadenopathies and three of the five patients with bilateral disease achieved objective response. In relapsed patients, response was observed both in previously irradiated and nonirradiated patients. The 2-year failure-free survival rate among the doxycycline-treated patients was 66% (95% confidence interval = 54 to 78), and 20 of the 27 patients were progression free.
CONCLUSIONS: Doxycycline is a fast, safe, and active therapy for Cp DNA-positive OAL that was effective even in patients with multiple failures involving previously irradiated areas or regional lymphadenopathies. The responses observed in PCR-negative OAL may suggest a need for development of more sensitive methods for Cp detection and investigation of the potential role of other doxycycline-sensitive bacteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018784     DOI: 10.1093/jnci/djj373

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  41 in total

Review 1.  Involvement of Helicobacter Pylori in Ocular Adnexa Lymphoma.

Authors:  Antonio Travaglino; Mirella Pace; Silvia Varricchio; Daniela Russo; Novella Pugliese; Alessandro Severino; Marco Picardi; Fabrizio Pane; Luigi Insabato; Stefania Staibano; Massimo Mascolo
Journal:  Pathol Oncol Res       Date:  2020-06-18       Impact factor: 3.201

Review 2.  [Chlamydial diseases of the eye. A short overview].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2007-01       Impact factor: 1.059

Review 3.  Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.

Authors:  Barbara Kiesewetter; Andrés J M Ferreri; Markus Raderer
Journal:  Oncologist       Date:  2015-07-08

Review 4.  Mitochondrial ribosomes in cancer.

Authors:  Hyun-Jung Kim; Priyanka Maiti; Antoni Barrientos
Journal:  Semin Cancer Biol       Date:  2017-04-23       Impact factor: 15.707

5.  Descriptive epidemiology of ophthalmic and ocular adnexal non-Hodgkin's lymphoma.

Authors:  Roxana Moslehi; F Bruce Coles; Maria J Schymura
Journal:  Expert Rev Ophthalmol       Date:  2011

Review 6.  The 2017 Doyne Lecture: the orbit as a window to systemic disease.

Authors:  A A McNab
Journal:  Eye (Lond)       Date:  2017-11-10       Impact factor: 3.775

Review 7.  Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.

Authors:  Sabarish Ayyappan; Basem M William
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

8.  Associations of Autoimmunity, Immunodeficiency, Lymphomagenesis, and Gut Microbiota in Mice with Knockins for a Pathogenic Autoantibody.

Authors:  Shweta Jain; Jerrold M Ward; Dong-Mi Shin; Hongsheng Wang; Zohreh Naghashfar; Alexander L Kovalchuk; Herbert C Morse
Journal:  Am J Pathol       Date:  2017-07-17       Impact factor: 4.307

Review 9.  Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

Authors:  Richard J Bende; Febe van Maldegem; Carel J M van Noesel
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  Treatment options for ocular adnexal lymphoma (OAL).

Authors:  Victoria Mary Lendrum Cohen
Journal:  Clin Ophthalmol       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.